Home Health News Novel Drug for HER2-Mutant Lung Cancer Wins FDA Approval By News Health 3 weeks Ago Share on FacebookShare on Twitter (MedPage Today) — The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations. Approval of the tyrosine… Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116921 Author : Publish date : 2025-08-08 21:19:00 Copyright for syndicated content belongs to the linked Source. Categories: Health News Related Content High-Dose Flu Shot May Cut Some Hospitalizations in Older Adults By News Health August 30, 2025 'Slimming jabs have changed the way we do things' By News Health August 30, 2025 Novel Oral Agent Proves Mettle in Obstructive Hypertrophic Cardiomyopathy By News Health August 30, 2025 State Laws on Unilateral Decisions for Life Support Are All Over the Map By News Health August 29, 2025 Getting a COVID Shot Just Became Much More Difficult. Here's Why. By News Health August 29, 2025 'Weekend Warriors' See Lower Gout Risk, Similar to Gym Rats By News Health August 29, 2025